Segregation of signaling proteins as prognostic predictors for local recurrence and distant metastasis in hepatocellular carcinoma

International Journal of Oncology

Volumn 44, Issue 2, 2014, Pages 491-504

  Yeh, Chau Ting ^a,b   Huang, Ya Hui ^a   Liang, Kung Hao ^a   Chang, Ming Ling ^a   Hsu, Chao Wei ^a   Chen, Yi Cheng ^a   Chen, Tse Ching ^a   Yeh, Ta Sen ^a   Lee, Wei Chen ^a  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

Extrahepatic metastasis; Hepatocellular carcinoma; Local recurrence; Signaling proteins; Survival

Indexed keywords

BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; COHORT STUDIES; FEMALE; HEP G2 CELLS; HUMANS; IMMUNOENZYME TECHNIQUES; LIVER; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84894429094     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2013.2198     Document Type: Article

References (36)

1. Parkin DM, Bray F, Ferlay J and Pisani P: Estimating the world cancer burden: Globocan 2000. Int J Cancer 94: 153-156, 2001. (Pubitemid 32911406)
2. Perz JF, Armstrong GL, Farrington LA, Hutin YJ and Bell BP: The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 45: 529-538, 2006. (Pubitemid 44307383)
3. Tanaka K, Hirohata T, Takeshita S, Hirohata I, Koga S, Sugimachi K, Kanematsu T, Ohryohji F and Ishibashi H: Hepatitis B virus, cigarette smoking and alcohol consumption in the development of hepatocellular carcinoma: a case-control study in Fukuoka, Japan. Int J Cancer 51: 509-514, 1992.
4. Bosch FX, Ribes J, Cleries R and Diaz M: Epidemiology of hepatocellular carcinoma. Clin Liver Dis 9: 191-211, 2005.
5. El-Serag HB: Hepatocellular carcinoma: recent trends in the United States. Gastroenterology 127: S27-S34, 2004.
6. Sherman M: Hepatocellular carcinoma: epidemiology, risk factors, and screening. Semin Liver Dis 25: 143-154, 2005.
7. Park NH, Song IH and Chung YH: Chronic hepatitis B in hepatocarcinogenesis. Postgrad Med J 82: 507-515, 2006. (Pubitemid 44258625)
8. Chau GY, Wu CW, Lui WY, Chang TJ, Kao HL, Wu LH, King KL, Loong CC, Hsia CY and Chi CW: Serum interleukin-10 but not interleukin-6 is related to clinical outcome in patients with resectable hepatocellular carcinoma. Ann Surg 231: 552-558, 2000.
9. Hsu YC, Fu HH, Jeng YM, Lee PH and Yang SD: Proline-directed protein kinase FA is a powerful and independent prognostic predictor for progression and patient survival of hepatocellular carcinoma. J Clin Oncol 24: 3780-3788, 2006.
10. Kitamoto M, Nakanishi T, Kira S, Kawaguchi M, Nakashio R, Suemori S, Kajiyama G, Asahara T and Dohi K: The assessment of proliferating cell nuclear antigen immunohistochemical staining in small hepatocellular carcinoma and its relationship to histologic characteristics and prognosis. Cancer 72: 1859-1865, 1993. (Pubitemid 23262112)
11. Kobayashi T, Kubota K, Takayama T and Makuuchi M: Telomerase activity as a predictive marker for recurrence of hepatocellular carcinoma after hepatectomy. Am J Surg 181: 284-288, 2001. (Pubitemid 32480232)
12. Poon RT, Lau CP, Ho JW, Yu WC, Fan ST and Wong J: Tissue factor expression correlates with tumor angiogenesis and invasiveness in human hepatocellular carcinoma. Clin Cancer Res 9: 5339-5345, 2003. (Pubitemid 37413589)
13. Poon RT, Ng IO, Lau C, Zhu LX, Yu WC, Lo CM, Fan ST and Wong J: Serum vascular endothelial growth factor predicts venous invasion in hepatocellular carcinoma: a prospective study. Ann Surg 233: 227-235, 2001. (Pubitemid 32106077)
14. Shen HM and Ong CN: Mutations of the p53 tumor suppressor gene and ras oncogenes in aflatoxin hepatocarcinogenesis. Mutat Res 366: 23-44, 1996.
15. Tsujita E, Taketomi A, Gion T, Kuroda Y, Endo K, Watanabe A, Nakashima H, Aishima S, Kohnoe S and Maehara Y: Suppressed MKP-1 is an independent predictor of outcome in patients with hepatocellular carcinoma. Oncology 69: 342-347, 2005. (Pubitemid 41752803)
16. Uenishi T, Kubo S, Yamamoto T, Shuto T, Ogawa M, Tanaka H, Tanaka S, Kaneda K and Hirohashi K: Cytokeratin 19 expression in hepatocellular carcinoma predicts early postoperative recurrence. Cancer Sci 94: 851-857, 2003. (Pubitemid 37406966)
17. Lee TK, Poon RT, Yuen AP, Ling MT, Kwok WK, Wang XH, Wong YC, Guan XY, Man K, Chau KL and Fan ST: Twist overexpression correlates with hepatocellular carcinoma metastasis through induction of epithelial-mesenchymal transition. Clin Cancer Res 12: 5369-5376, 2006. (Pubitemid 44497250)
18. Zhu K, Dai Z, Pan Q, Wang Z, Yang GH, Yu L, Ding ZB, Shi GM, Ke AW, Yang XR, Tao ZH, Zhao YM, Qin Y, Zeng HY, Tang ZY, Fan J and Zhou J: Metadherin promotes hepatocellular carcinoma metastasis through induction of epithelial-mesenchymal transition. Clin Cancer Res 17: 7294-7302, 2011.
19. Eisen MB, Spellman PT, Brown PO and Botstein D: Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 95: 14863-14868, 1998. (Pubitemid 29003722)
20. Saldanha AJ: Java Treeview - extensible visualization of microarray data. Bioinformatics 20: 3246-3248, 2004.
21. Mazumdar M and Glassman JR: Categorizing a prognostic variable: review of methods, code for easy implementation and applications to decision-making about cancer treatments. Stat Med 19: 113-132, 2000. (Pubitemid 30051256)
22. Trevisani F, Cantarini MC, Wands JR and Bernardi M: Recent advances in the natural history of hepatocellular carcinoma. Carcinogenesis 29: 1299-1305, 2008.
23. Chen R, Yang Q and Lee JD: BMK1 kinase suppresses epithelial-mesenchymal transition through the Akt/GSK3beta signaling pathway. Cancer Res 72: 1579-1587, 2012.
24. Fenouille N, Tichet M, Dufies M, Pottier A, Mogha A, Soo JK, Rocchi S, Mallavialle A, Galibert MD, Khammari A, Lacour JP, Ballotti R, Deckert M and Tartare-Deckert S: The epithelial-mesenchymal transition (EMT) regulatory factor SLUG (SNAI2) is a downstream target of SPARC and AKT in promoting melanoma cell invasion. PLoS One 7: e40378, 2012.
25. Jiao M and Nan KJ: Activation of PI3 kinase/Akt/HIF-1alpha pathway contributes to hypoxia-induced epithelial-mesenchymal transition and chemoresistance in hepatocellular carcinoma. Int J Oncol 40: 461-468, 2012.
26. Maseki S, Ijichi K, Tanaka H, Fujii M, Hasegawa Y, Ogawa T, Murakami S, Kondo E and Nakanishi H: Acquisition of EMT phenotype in the gefitinib-resistant cells of a head and neck squamous cell carcinoma cell line through Akt/GSK-3beta/snail signalling pathway. Br J Cancer 106: 1196-1204, 2012.
27. Ogunwobi OO and Liu C: Hepatocyte growth factor upregulation promotes carcinogenesis and epithelial-mesenchymal transition in hepatocellular carcinoma via Akt and COX-2 pathways. Clin Exp Metastasis 28: 721-731, 2011.
28. Ogunwobi OO, Wang T, Zhang L and Liu C: Cyclooxygenase-2 and Akt mediate multiple growth-factor-induced epithelial-mesenchymal transition in human hepatocellular carcinoma. J Gastroenterol Hepatol 27: 566-578, 2012.
29. Wen W, Ding J, Sun W, Fu J, Chen Y, Wu K, Ning B, Han T, Huang L, Chen C, Xie D, Li Z, Feng G, Wu M, Xie W and Wang H: Cyclin G1-mediated epithelial-mesenchymal transition via phosphoinositide 3-kinase/Akt signaling facilitates liver cancer progression. Hepatology 55: 1787-1798, 2012.
30. Frese S, Pirnia F, Miescher D, Krajewski S, Borner MM, Reed JC and Schmid RA: PG490-mediated sensitization of lung cancer cells to Apo2L/TRAIL-induced apoptosis requires activation of ERK2. Oncogene 22: 5427-5435, 2003. (Pubitemid 37072197)
31. Liang X, Du J, Liu Y, Cui M, Ma C, Han L, Qu Z, Zhang Z, Sun Z, Zhang L, Chen YH and Sun W: The hepatitis B virus protein MHBs(t) sensitizes hepatoma cells to TRAIL-induced apoptosis through ERK2. Apoptosis 12: 1827-1836, 2007. (Pubitemid 47498249)
32. Bakarakos P, Theohari I, Nomikos A, Mylona E, Papadimitriou C, Dimopoulos AM and Nakopoulou L: Immunohistochemical study of PTEN and phosphorylated mTOR proteins in familial and sporadic invasive breast carcinomas. Histopathology 56: 876-882, 2010.
33. Hirashima K, Baba Y, Watanabe M, Karashima R, Sato N, Imamura Y, Hiyoshi Y, Nagai Y, Hayashi N, Iyama K and Baba H: Phosphorylated mTOR expression is associated with poor prognosis for patients with esophageal squamous cell carcinoma. Ann Surg Oncol 17: 2486-2493, 2010.
34. Li N, Zhong M and Song M: Expression of phosphorylated mTOR and its regulatory protein is related to biological behaviors of ameloblastoma. Int J Clin Exp Pathol 5: 660-667, 2012.
35. Ueng SH, Chen SC, Chang YS, Hsueh S, Lin YC, Chien HP, Lo YF, Shen SC and Hsueh C: Phosphorylated mTOR expression correlates with poor outcome in early-stage triple negative breast carcinomas. Int J Clin Exp Pathol 5: 806-813, 2012.
36. Yoshida Y, Kurokawa T, Horiuchi Y, Sawamura Y, Shinagawa A and Kotsuji F: Localisation of phosphorylated mTOR expression is critical to tumour progression and outcomes in patients with endometrial cancer. Eur J Cancer 46: 3445-3452, 2010.